Buy Rating Maintained for Apellis Pharmaceuticals: Strategic Market Position and Growth Potential Justify Price Objective
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) yesterday and set a ...
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.
Crinetics falls after mid-stage trial data adrenal disorder therapy
Crinetics Pharmaceuticals (CRNX) stock fell after Phase 2 results for its experimental drug atumelnant for congenital adrenal hyperplasia. Read more here.